Immune checkpoint blockade plus interferon-γ add-on antifungal therapy in the treatment of refractory Université Covid-associated pulmonary aspergillosis and cerebral mucormycosis

A. Serris¹, F. Uhel², E. Litvinova³, A. Ouedrani⁴, C. Rouzaud¹, V. Bedarida⁵, J-H. Raphalen⁶, O. Lambotte⁷, G. Martin-Blondel⁸, F. Lanternier^{1,9}

¹ Department of infectious diseases, Hôpital Necker-Enfants Malades, AP-HP, Université de Paris, Paris
² ICU, Hôpital Ambroise Paré, APHP, Paris
³ Department of immunology, Hôpital Pitié Salpétrière, AP-HP


potential benefit of checkpoint inhibitors.

de Paris

⁴ Department of immunology, Hôpital Necker-Enfants Malades, AP-HP, Paris
⁵ ENT surgical department, Lariboisière hospital, APHP, Paris
⁶ ICU, Necker-enfants malades hospital, APHP, Paris

⁷ Internal medicine department, Kremlin Bicêtre hospital, APHP, Kremlin Bicêtre
⁸ Department of infectious diseases, Toulouse Universitary hospital, Toulouse
⁹ National Reference Centre for Invasive Mycoses and Antifungals, UMR 2000, Institut Pasteur, CNRS, Paris

 Mucormycosis and aspergillosis are life-threatening fungal infections (IFI).
Rescue therapies are needed for patients not responding to conventional treatment. Recently published studies in animal models and human case reports suggest a






Figure 4. Evolution of the percentage of CD4 and CD8 T cells expressing PD-1 and HLA-DR under immunotherappy

- Although the patient did not survive, the initial clinical response obtained with anti-PD-1 plus IFN-γ add-on dual antifungal therapy and surgical management is encouraging.
- Combination immunotherapy might be considered as salvage treatment of lifethreatening IFI unresponsive to conventional therapy. Further studies will be needed to determine its optimal timing and role in the current therapeutic arsenal.
- As patients with IFI are usually particularly fragile and under a lot of concomitant medications, the use of immune checkpoint inhibitor must be carefully monitored (risk of severe, notably autoimmune, adverse effects).